Assessment of Reactance Parameters Measured by the Forced Oscillation Technique for the Bronchodilator Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03910985 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2019-04-17
Summary
The aims of this study is :
* to assess the bronchodilator (DUOVENT HFA) response of parameters measured by the forced oscillations (FOT) and in particular the reactance parameters related to the presence of a limitation of expiratory flows
* to compare the response of the reactance parameters to bronchodilators with the conventional spirometric parameters (FEV1) and inspiratory capacity (IC), and according to the severity of the disease
* to assess and compare the relationship between the response to bronchodilators in terms of IC on the one hand and on the other hand in terms of FEV1, reactance parameters (measured by FOT), resistance parameters (measured by plethysmography and FOT)
* Assess and compare the relationship between dyspnea intensity assessed by various scales and conventional respiratory function parameters (spirometry, plethysmography, diffusion indices) and parameters measured by FOT
Conditions
Interventions
- DRUG
-
Duovent HFA
bronchodilation
Sponsors & Collaborators
-
Centre Hospitalier Universitaire UCLouvain Namur
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-23
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
More Related Trials
-
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease
NCT01113593 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03979807 ·Status: COMPLETED
-
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01879410 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00545311 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
NCT02449018 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
NCT01342913 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
NCT01921127 ·Status: COMPLETED
-
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01119950 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients
NCT02119234 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure
NCT04522596 ·Status: RECRUITING ·Phase: PHASE4
-
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00691405 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD
NCT00280371 ·Status: COMPLETED ·Phase: PHASE3
-
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
NCT00929851 ·Status: COMPLETED ·Phase: PHASE3
-
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
NCT02182869 ·Status: TERMINATED ·Phase: PHASE2
-
Assessing Optimal Inhaler Strategies During Acute Exacerbations of COPD (AECOPDs) Using Oscillometry
NCT06495047 ·Status: COMPLETED
-
A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
NCT02643082 ·Status: COMPLETED ·Phase: PHASE3
-
Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
NCT01933984 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
NCT01398111 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00570778 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Patients With COPD
NCT00215384 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Oxygen Treatment Trial
NCT00692198 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
NCT02700919 ·Status: COMPLETED ·Phase: PHASE2
-
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
NCT00742248 ·Status: COMPLETED ·Phase: PHASE2
-
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
NCT02634983 ·Status: COMPLETED ·Phase: PHASE4
-
U-LABA/ICS Effects on Exercise Performance, Formoterol
NCT06105671 ·Status: COMPLETED ·Phase: NA